## Application for Special Authority

**Subsidy for Infliximab**

<table>
<thead>
<tr>
<th>Application Category</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graft vs host disease - Initial application</td>
<td>2</td>
</tr>
<tr>
<td>Pulmonary sarcoidosis - Initial application</td>
<td>2</td>
</tr>
<tr>
<td>Previous use - Initial application</td>
<td>3</td>
</tr>
<tr>
<td>Rheumatoid arthritis - Initial application</td>
<td>4</td>
</tr>
<tr>
<td>Ankylosing spondylitis - Initial application</td>
<td>4</td>
</tr>
<tr>
<td>Psoriatic arthritis - Initial application</td>
<td>5</td>
</tr>
<tr>
<td>Severe ocular inflammation - Initial application</td>
<td>5</td>
</tr>
<tr>
<td>Chronic ocular inflammation - Initial application</td>
<td>6</td>
</tr>
<tr>
<td>Crohn's disease (adults) - Initial application</td>
<td>6</td>
</tr>
<tr>
<td>Crohn's disease (children) - Initial application</td>
<td>7</td>
</tr>
<tr>
<td>Fistulising Crohn's disease - Initial application</td>
<td>7</td>
</tr>
<tr>
<td>Acute severe fulminant ulcerative colitis - Initial application</td>
<td>8</td>
</tr>
<tr>
<td>Severe ulcerative colitis - Initial application</td>
<td>8</td>
</tr>
<tr>
<td>Plaque psoriasis - Initial application</td>
<td>9</td>
</tr>
<tr>
<td>Neurosarcoidosis - Initial application</td>
<td>9</td>
</tr>
<tr>
<td>Severe Behcet's disease - Initial application</td>
<td>10</td>
</tr>
<tr>
<td>Rheumatoid arthritis - Renewal</td>
<td>10</td>
</tr>
<tr>
<td>Ankylosing spondylitis - Renewal</td>
<td>10</td>
</tr>
<tr>
<td>Psoriatic arthritis - Renewal</td>
<td>10</td>
</tr>
<tr>
<td>Severe ocular inflammation - Renewal</td>
<td>11</td>
</tr>
<tr>
<td>Chronic ocular inflammation - Renewal</td>
<td>11</td>
</tr>
<tr>
<td>Crohn's disease (adults) - Renewal</td>
<td>12</td>
</tr>
<tr>
<td>Crohn's disease (children) - Renewal</td>
<td>12</td>
</tr>
<tr>
<td>Fistulising Crohn's disease - Renewal</td>
<td>13</td>
</tr>
<tr>
<td>Severe fulminant ulcerative colitis - Renewal</td>
<td>13</td>
</tr>
<tr>
<td>Severe ulcerative colitis - Renewal</td>
<td>13</td>
</tr>
<tr>
<td>Plaque psoriasis - Renewal</td>
<td>14</td>
</tr>
<tr>
<td>Neurosarcoidosis - Renewal</td>
<td>14</td>
</tr>
<tr>
<td>Severe Behcet's disease - Renewal</td>
<td>15</td>
</tr>
</tbody>
</table>
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

APPLICANT (stamp or sticker acceptable) 
Reg No: ...........................................
Name: .......................................................
Address: .......................................................
Fax Number: .......................................................

PATIENT NHI: .......................................................
First Names: .......................................................
Surname: .......................................................
DOB: .......................................................
Address: .......................................................
Fax Number: .......................................................

REFERRER Reg No: ...........................................
First Names: .......................................................
Surname: .......................................................
Address: .......................................................
Fax Number: .......................................................

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: .......................................................
Date: .......................................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Ministry of Health
Phone 0800 243 666

APPLICANT  (stamp or sticker acceptable)  PATIENT  NHI: ..................................................  REFERRER  Reg No: ......................................................

Reg No: ........................................................................  First Names: ..............................................................

Name: ...........................................................................  Surname: ................................................................

Address: ........................................................................  Address: ........................................................................

..............................................................................

..............................................................................

Fax Number: ..............................................................  Fax Number: ..............................................................

PATIENT
NHI: ....................................................

First Names: ........................................................

Surname: ..............................................................

DOB: ......................................................................

Address: ...............................................................  Address: ........................................................................

..............................................................................

..............................................................................

REFERRER
Reg No: ..........................................

First Names: ........................................................

Surname: ..............................................................

Address: ...............................................................  Address: ........................................................................

..............................................................................

..............................................................................

APPLICATION FOR SUBSIDY - continued

INFILIXIMAB

INITIAL APPLICATION - previous use
Applications from any relevant practitioner. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

☐ Patient was being treated with infliximab prior to 1 February 2019

and

☐ Rheumatoid arthritis

or

☐ Ankylosing spondylitis

or

☐ Psoriatic arthritis

or

☐ Severe ocular inflammation

or

☐ Chronic ocular inflammation

or

☐ Crohn’s disease (adults)

or

☐ Crohn’s disease (children)

or

☐ Fistulising Crohn’s disease

or

☐ Severe fulminant ulcerative colitis

or

☐ Severe ulcerative colitis

or

☐ Plaque psoriasis

or

☐ Neurosarcoïdosis

or

☐ Severe Behcet’s disease

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ................................................................. Date: ............................................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

APPLICANT (stamp or sticker acceptable)  PATIENT NHI: ..........................................................
Reg No: ..........................................................  First Names: ..........................................................
Name: ..........................................................  Surname: ..........................................................
Address: ..........................................................
Fax Number: ..........................................................

PATIENT
NHI: ..........................................................
First Names: ..........................................................
Surname: ..........................................................
DOB: ..........................................................
Address: ..........................................................
Fax Number: ..........................................................

REFERRER  Reg No: ..........................................................
First Names: ..........................................................
Surname: ..........................................................
Address: ..........................................................
Fax Number: ..........................................................

INITIAL APPLICATION - rheumatoid arthritis
Applications only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months.
Prerequisites (tick boxes where appropriate)

☐ The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis
and
☐ The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept
or
☐ Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept
and
☐ Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

INITIAL APPLICATION - ankylosing spondylitis
Applications only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 3 months.
Prerequisites (tick boxes where appropriate)

☐ The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis
and
☐ The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept
or
☐ Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis

INITIAL APPLICATION - psoriatic arthritis
Applications only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months.
Prerequisites (tick boxes where appropriate)

☐ The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis
and
☐ The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept
or
☐ Following 3-4 months’ initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..........................................................
Date: ..........................................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ................................................................. Date: ...............................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

APPLICANT (stamp or sticker acceptable)  PATIENT NHI: .............................................  REFERRER Reg No: .............................................
Reg No: .............................................................  First Names: ....................................................  First Names: ....................................................
Name: .............................................................  Surname: ........................................................  Surname: ........................................................
Address: ............................................................  Address: ............................................................  Address: ............................................................
Fax Number: ........................................................  Fax Number: ........................................................

PATIENT
NHI: .............................................................
First Names: ....................................................
Surname: ........................................................
DOB: .............................................................
Address: ............................................................
...............................................................................
...............................................................................

REFERRER
Reg No: .............................................................
First Names: ....................................................
Surname: ........................................................
Address: ............................................................
...............................................................................
...............................................................................
Fax Number: ........................................................

APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Infliximab  - continued

INITIAL APPLICATION - Crohn’s disease (adults)
Applications only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months.

Prerequisites (tick boxes where appropriate)

❑ Patient has severe active Crohn's disease
and
❑ Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300
or
❑ Patient has extensive small intestine disease affecting more than 50 cm of the small intestine
or
❑ Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection
or
❑ Patient has an ileostomy or colostomy, and has intestinal inflammation
and
❑ Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids
and
❑ Surgery (or further surgery) is considered to be clinically inappropriate
and
❑ Patient must be reassessed for continuation after 3 months of therapy

INITIAL APPLICATION - Crohn’s disease (children)
Applications only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months.

Prerequisites (tick boxes where appropriate)

❑ Paediatric patient has severe active Crohn's disease
and
❑ Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30
or
❑ Patient has extensive small intestine disease
and
❑ Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids
and
❑ Surgery (or further surgery) is considered to be clinically inappropriate
and
❑ Patient must be reassessed for continuation after 3 months of therapy

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: .............................................................  Date: ............................................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Wednesday, June 2019

**APPLICANT** (stamp or sticker acceptable)
Reg No: ..............................................................
Name: ..............................................................
Address: .............................................................
Fax Number: ........................................................

**PATIENT**
NHI: ..............................................................
First Names: ......................................................
Surname: ............................................................
Address: .............................................................
...............................................................................
...............................................................................
Fax Number: ........................................................

**REFERRER**
Reg No: ..............................................................
First Names: ......................................................
Surname: ............................................................
Address: .............................................................
...............................................................................
Fax Number: ........................................................

**APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY**

**Infliximab** - continued

<table>
<thead>
<tr>
<th><strong>INITIAL APPLICATION</strong> - fistulising Crohn’s disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applications only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 4 months.</td>
</tr>
<tr>
<td><strong>Prerequisites</strong> (tick boxes where appropriate)</td>
</tr>
<tr>
<td>❑ Patient has confirmed Crohn’s disease</td>
</tr>
<tr>
<td>and</td>
</tr>
<tr>
<td>❑ Patient has one or more complex externally draining enterocutaneous fistula(e)</td>
</tr>
<tr>
<td>or</td>
</tr>
<tr>
<td>❑ Patient has one or more rectovaginal fistula(e)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>INITIAL APPLICATION</strong> - acute severe fulminant ulcerative colitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applications only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 weeks.</td>
</tr>
<tr>
<td><strong>Prerequisites</strong> (tick boxes where appropriate)</td>
</tr>
<tr>
<td>❑ Patient has acute, severe fulminant ulcerative colitis</td>
</tr>
<tr>
<td>and</td>
</tr>
<tr>
<td>❑ Treatment with intravenous or high dose oral corticosteroids has not been successful</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>INITIAL APPLICATION</strong> - severe ulcerative colitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applications only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months.</td>
</tr>
<tr>
<td><strong>Prerequisites</strong> (tick boxes where appropriate)</td>
</tr>
<tr>
<td>❑ Patient has histologically confirmed ulcerative colitis</td>
</tr>
<tr>
<td>and</td>
</tr>
<tr>
<td>❑ Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4</td>
</tr>
<tr>
<td>or</td>
</tr>
<tr>
<td>❑ Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65</td>
</tr>
<tr>
<td>and</td>
</tr>
<tr>
<td>❑ Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids</td>
</tr>
<tr>
<td>and</td>
</tr>
<tr>
<td>❑ Surgery (or further surgery) is considered to be clinically inappropriate</td>
</tr>
</tbody>
</table>

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: .............................................................. Date: ..............................................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Infliximab - continued

INITIAL APPLICATION - plaque psoriasis
Applications only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 3 months.

Prerequisites (tick boxes where appropriate)

- The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis

- The patient has experienced intolerable side effects from adalimumab or etanercept

- The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis

- Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis

- Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis

- Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin

- A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course

- The most recent PASI assessment is no more than 1 month old at the time of initiation

Note:
"Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: .......................................................... Date: ..............................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
**APPLICATION FOR SUBSIDY**

**BY SPECIAL AUTHORITY**

---

**APPLICANT**

(stamp or sticker acceptable)

<table>
<thead>
<tr>
<th>Reg No: .......................................................</th>
<th>Name: ...................................................................</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address: ...................................................</td>
<td>Address: ..................................................................</td>
</tr>
<tr>
<td>...........................................................................</td>
<td>.............................................................................</td>
</tr>
<tr>
<td>...........................................................................</td>
<td>.............................................................................</td>
</tr>
<tr>
<td>Fax Number: ................................................</td>
<td>.............................................................................</td>
</tr>
</tbody>
</table>

**PATIENT**

NHI: ......................................................

<table>
<thead>
<tr>
<th>First Names: ........................................</th>
<th>Surname: ......................................................</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address: ................................................</td>
<td>Address: ..................................................................</td>
</tr>
<tr>
<td>...........................................................................</td>
<td>.............................................................................</td>
</tr>
<tr>
<td>...........................................................................</td>
<td>.............................................................................</td>
</tr>
</tbody>
</table>

**REFERRER**

Reg No: ..........................................

<table>
<thead>
<tr>
<th>First Names: ........................................</th>
<th>Surname: ......................................................</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address: ................................................</td>
<td>Address: ..................................................................</td>
</tr>
<tr>
<td>...........................................................................</td>
<td>.............................................................................</td>
</tr>
<tr>
<td>...........................................................................</td>
<td>.............................................................................</td>
</tr>
<tr>
<td>Fax Number: ................................................</td>
<td>.............................................................................</td>
</tr>
</tbody>
</table>

**INFliximab** - continued

---

**INITIAL APPLICATION - neurosarcoiosis**

Applications only from a neurologist or Practitioner on the recommendation of a neurologist. Approvals valid for 18 months.

**Prerequisites** (tick boxes where appropriate)

- [ ] Patient has been diagnosed with neurosarcoiosis by a multidisciplinary team
- [ ] Patient has CNS involvement
- [ ] Patient has steroid-refractory disease

- [ ] IV cyclophosphamide has been tried
  - or
  - Treatment with IV cyclophosphamide is clinically inappropriate

**INITIAL APPLICATION - severe Behcet’s disease**

Applications from any relevant practitioner. Approvals valid for 4 months.

**Prerequisites** (tick boxes where appropriate)

- [ ] The patient has severe Behcet’s disease which is significantly impacting the patient’s quality of life (see Notes)

  - and

  - [ ] The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes)
    - or
    - [ ] The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes)

- [ ] The patient is experiencing significant loss of quality of life

**Note:**


Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

---

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: .................................................. Date: ...........................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Form SA1778
June 2019

APPLICANT
(Stamp or sticker acceptable)

PATIENT
NHI: ...................................................................

REFFERER
Reg No: ....................................... 

Reg No: ................................ ........

Name: ...............................................................

First Names: ............................................................

Surname: ..............................................................

DOB: ....................................................................

Address: ................................................................

...............................................................................

...............................................................................

Fax Number: ........................................................

APPLICANT
(Stamp or sticker acceptable)

NHI: .......................................................

First Names: ............................................................

Surname: ..............................................................

DOB: ....................................................................

Address: ................................................................

...............................................................................

...............................................................................

Fax Number: ........................................................

REFERRER
Reg No: ..........................................

First Names: ............................................................

Surname: ..............................................................

DOB: ....................................................................

Address: ................................................................

...............................................................................

...............................................................................

Fax Number: ........................................................

APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Infliximab - continued

RENEWAL - rheumatoid arthritis
Current approval Number (if known): .................................

Applications only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

- Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

- Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

- Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks

RENEWAL - ankylosing spondylitis
Current approval Number (if known): .................................

Applications only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

- Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less

- Physician considers that the patient has benefited from treatment and that continued treatment is appropriate

- Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks

RENEWAL - psoriatic arthritis
Current approval Number (if known): .................................

Applications only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

- Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

- The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician

- Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: .............................................................................. Date: ...............................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Infliximab - continued

RENEWAL - severe ocular inflammation
Current approval Number (if known): ..............................................................
Applications from any relevant practitioner. Approvals valid for 12 months.

Prerequisites (tick boxes where appropriate)

❑ The patient has had a good clinical response following 3 initial doses
or
❑ The patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema), following 12 months' treatment
or
❑ The patient has a sustained steroid sparing effect, allowing reduction in prednisone to <10mg daily, or steroid drops less than twice daily if under 18 years old, following 12 months’ treatment

Note:
A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

RENEWAL - chronic ocular inflammation
Current approval Number (if known): ..............................................................
Applications from any relevant practitioner. Approvals valid for 12 months.

Prerequisites (tick boxes where appropriate)

❑ The patient has had a good clinical response following 3 initial doses
or
❑ The patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema), following 12 months' treatment
or
❑ The patient has a sustained steroid sparing effect, allowing reduction in prednisone to <10mg daily, or steroid drops less than twice daily if under 18 years old, following 12 months’ treatment

Note:
A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Form SA1778
June 2019

Ministry of Health
Phone 0800 243 666

APPLICANT (stamp or sticker acceptable)
Reg No: .................................................. Name: ...........................................................

Address: ...........................................................
...............................................................................
...............................................................................

Fax Number: ........................................................

PATIENT
NHI: ..........................................................
First Names: ..................................................
Surname: .....................................................
DOB: ..........................................................
Address: ...........................................................
...............................................................................
...............................................................................

Fax Number: ........................................................

REFERRER
Reg No: ..........................................
First Names: ..................................................
Surname: .....................................................
Address: ...........................................................
...............................................................................
...............................................................................
Fax Number: ........................................................

APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Infliximab - continued

RENEWAL - Crohn’s disease (adults)

Current approval Number (if known): ...............................................................

Applications only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

☐ CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab

or

☐ CDAI score is 150 or less

or

☐ The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed

and

☐ Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019

RENEWAL - Crohn’s disease (children)

Current approval Number (if known): ...............................................................

Applications only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

☐ PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab

or

☐ PCDAI score is 15 or less

or

☐ The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed

and

☐ Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: .......................................................... Date: .............................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

APPLICANT (stamp or sticker acceptable)  PATIENT  NHI:  .....................................................  REFERRER  Reg No:  .....................................................

Reg No:  ..............................................................  First Names:  ..............................................................  First Names:  ..............................................................

Name:  ..............................................................  Surname:  ..............................................................  Surname:  ..............................................................

Address:  ................................................................  Address:  ................................................................  Address:  ................................................................

.............................................................................  .............................................................................  .............................................................................

Fax Number:  ........................................................  Fax Number:  ........................................................  Fax Number:  ........................................................

RENEWAL - fistulising Crohn’s disease

Current approval Number (if known):  ..............................................................

Applications only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

❑ The number of open draining fistulae have decreased from baseline by at least 50%

or

❑ There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain

and

❑ Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019

RENEWAL - severe fulminant ulcerative colitis

Current approval Number (if known):  ..............................................................

Applications only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

❑ Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months

and

❑ Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019

RENEWAL - severe ulcerative colitis

Current approval Number (if known):  ..............................................................

Applications only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

❑ Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks

and

❑ Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab

or

❑ Patient is under 18 years and the PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab

and

❑ Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed:  ..............................................................  Date:  ..............................................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Ministry of Health
Phone 0800 243 666

APPLICANT (stamp or sticker acceptable)  PATIENT NHI: ...........................................
Reg No: ...........................................
Name: ...........................................
Address: ...........................................
Fax Number: ...........................................

PATIENT NHI: ...........................................
First Names: ...........................................
Surname: ...........................................
DOB: ...........................................
Address: ...........................................
Fax Number: ...........................................

REG No: ...........................................
First Names: ...........................................
Surname: ...........................................
Address: ...........................................
Fax Number: ...........................................

APPLICATION FOR SUBSIDY
BY SPECIAL AUTHORITY

Infliximab - continued

RENEWAL - plaque psoriasis
Current approval Number (if known): ............................................
Applications only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

- ☐ Patient had "whole body" severe chronic plaque psoriasis at the start of treatment
- ☐ Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value

or

- ☐ Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment
- ☐ Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values

or

- ☐ Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value

- ☐ Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks

RENEWAL - neurosarcoidosis
Current approval Number (if known): ............................................
Applications only from a neurologist or Practitioner on the recommendation of a neurologist. Approvals valid for 18 months.

Prerequisites (tick boxes where appropriate)

- ☐ A withdrawal period has been tried and the patient has relapsed

or

- ☐ A withdrawal period has been considered but would not be clinically appropriate

and

- ☐ There has been a marked reduction in prednisone dose

and

- ☐ There has been an improvement in MRI appearances

or

- ☐ Marked improvement in other symptomology

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ............................................ Date: ............................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

APPLICANT (stamp or sticker acceptable)            PATIENT NHI: ..................................................            REFERRER Reg No: ..................................................
Reg No: ................................................................. First Names: ................................................................. First Names: .................................................................
Name: ........................................................................ Surname: ................................................................. Surname: .................................................................
Address: ........................................................................ DOB: ................................................................. Address: ........................................................................
........................................................................ Fax Number: .................................................................
........................................................................

Infliximab - continued

RENEWAL - severe Behcet's disease
Current approval Number (if known): ..................................................

Applications from any relevant practitioner. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

☐ Patient has had a good clinical response to initial treatment with measurably improved quality of life

and

☐ Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ........................................................................ Date: ...............................................

Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131